Sign in
Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of Great Than or Equal to 4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Annual Meeting Talks
2019
PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration
David T.W. Wong, MD, FRCS(C), FASRS
Updates from the Field
2025
Effect of 6 month anti-VEGF treatment for proliferative diabetic retinopathy on the quantitative metrics of the retinal microvasculature on OCTA
Quan V. Hoang, MD, PhD
On Demand Cases, Courses, and Papers
Category: Pharmacology